U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07124000) titled 'DESTINY-PANTUMOUR04' on Aug. 13.

Brief Summary: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Study Start Date: Aug. 31

Study Type: OBSERVATIONAL

Condition: Adenocarcinoma (NOS) Anal Cancer Bladder Cancer Cervical Cancer Endometrial Cancer Esophageal Cancer Gall Bladder Cancer Gastrointestinal Stromal Tumour Head and Neck Cancer Liver Cancer Melanoma Mouth Cance...